Chimerix Azione

Chimerix Debiti verso fornitori

Delisted·17 apr 2025

Il Debiti Commerciali di Chimerix (CMRX) al 26 ago 2026 è 3,94 Mio. USD. L'anno precedente, Debiti Commerciali era 2,85 Mio. USD — una variazione del 38,13% (superiore).

Debiti verso fornitori

3,94 Mio.USD

YoY

38,13%

Ultimo aggiornamento:

Debiti Commerciali di Chimerix ammonta a 2026 3,94 Mio. USD. Debiti Commerciali di Chimerix ammontava a 2025 2,85 Mio. USD. Diminuisce del 38,13% superiore rispetto all'anno precedente.

La storia di Chimerix Debiti verso fornitori

  • 3 anni

  • 10 anni

  • 25 anni

  • Max

Debiti verso fornitori
Date
Debiti verso fornitori
1 gen 2017
3,81 Mio. USD
1 gen 2018
4,69 Mio. USD
1 gen 2019
2,40 Mio. USD
1 gen 2020
1,28 Mio. USD
1 gen 2021
2,79 Mio. USD
1 gen 2022
3,03 Mio. USD
1 gen 2023
2,85 Mio. USD
1 gen 2024
3,94 Mio. USD
La storia di Chimerix Debiti verso fornitori
ANNODebiti verso fornitoriYoY
3,94 Mio.USD+38,13%
2,85 Mio.USD-6,03%
3,03 Mio.USD+8,82%
2,79 Mio.USD+117,30%
1,28 Mio.USD-46,50%
2,40 Mio.USD-48,88%
4,69 Mio.USD+23,06%
3,81 Mio.USD-2,01%
3,89 Mio.USD-62,80%
10,46 Mio.USD+76,12%
5,94 Mio.USD
Access this data via the Eulerpool API

Chimerix Analisi delle Azioni

Cosa fa Chimerix? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Chimerix azioni

Debiti Commerciali di Chimerix è 3,94 Mio. USD nel 2026.

Il Debiti Commerciali di Chimerix è passato da 2,85 Mio. USD a 3,94 Mio. USD, con una variazione del 38,13 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Chimerix di Debiti Commerciali dal 2006, con valori annuali, grafici e analisi dettagliate.

I debiti commerciali rappresentano il denaro dovuto ai fornitori per beni e servizi ricevuti. È un componente fondamentale della gestione del capitale di esercizio.

Il USD di Debiti Commerciali è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il Chimerix di Debiti Commerciali storicamente e in tempo reale.

Access this data via the Eulerpool API

Bilancio — Chimerix

Tutte le Metriche Finanziarie — Chimerix